Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bernard Fine is active.

Publication


Featured researches published by Bernard Fine.


Cancer Research | 2005

A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients

Hongyue Dai; Laura J. van 't Veer; John Lamb; Yudong D. He; Mao Mao; Bernard Fine; René Bernards; Marc J. van de Vijver; Paul J. Deutsch; Alan B. Sachs; Roland Stoughton; Stephen H. Friend

Breast cancer comprises a group of distinct subtypes that despite having similar histologic appearances, have very different metastatic potentials. Being able to identify the biological driving force, even for a subset of patients, is crucially important given the large population of women diagnosed with breast cancer. Here, we show that within a subset of patients characterized by relatively high estrogen receptor expression for their age, the occurrence of metastases is strongly predicted by a homogeneous gene expression pattern almost entirely consisting of cell cycle genes (5-year odds ratio of metastasis, 24.0; 95% confidence interval, 6.0-95.5). Overexpression of this set of genes is clearly associated with an extremely poor outcome, with the 10-year metastasis-free probability being only 24% for the poor group, compared with 85% for the good group. In contrast, this gene expression pattern is much less correlated with the outcome in other patient subpopulations. The methods described here also illustrate the value of combining clinical variables, biological insight, and machine-learning to dissect biological complexity. Our work presented here may contribute a crucial step towards rational design of personalized treatment.


Blood | 2005

Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia

Gunnar Cario; Martin Stanulla; Bernard Fine; Oliver Teuffel; Nils von Neuhoff; André Schrauder; Thomas Flohr; Beat W. Schäfer; Claus R. Bartram; Karl Welte; Brigitte Schlegelberger; Martin Schrappe

Treatment resistance, as indicated by the presence of high levels of minimal residual disease (MRD) after induction therapy and induction consolidation, is associated with a poor prognosis in childhood acute lymphoblastic leukemia (ALL). We hypothesized that treatment resistance is an intrinsic feature of ALL cells reflected in the gene expression pattern and that resistance to chemotherapy can be predicted before treatment. To test these hypotheses, gene expression signatures of ALL samples with high MRD load were compared with those of samples without measurable MRD during treatment. We identified 54 genes that clearly distinguished resistant from sensitive ALL samples. Genes with low expression in resistant samples were predominantly associated with cell-cycle progression and apoptosis, suggesting that impaired cell proliferation and apoptosis are involved in treatment resistance. Prediction analysis using randomly selected samples as a training set and the remaining samples as a test set revealed an accuracy of 84%. We conclude that resistance to chemotherapy seems at least in part to be an intrinsic feature of ALL cells. Because treatment response could be predicted with high accuracy, gene expression profiling could become a clinically relevant tool for treatment stratification in the early course of childhood ALL.


BMC Medical Genomics | 2009

Diurnal variation of the human adipose transcriptome and the link to metabolic disease

Andrey Loboda; Walter K. Kraft; Bernard Fine; Jeffrey I. Joseph; Michael Nebozhyn; Chunsheng Zhang; Yudong He; Xia Yang; Christopher Wright; Mark Morris; Ira Chalikonda; Mark Ferguson; Valur Emilsson; Amy Leonardson; John Lamb; Hongyue Dai; Eric E. Schadt; Howard E. Greenberg; Pek Yee Lum

BackgroundCircadian (diurnal) rhythm is an integral part of the physiology of the body; specifically, sleep, feeding behavior and metabolism are tightly linked to the light-dark cycle dictated by earths rotation.MethodsThe present study examines the effect of diurnal rhythm on gene expression in the subcutaneous adipose tissue of overweight to mildly obese, healthy individuals. In this well-controlled clinical study, adipose biopsies were taken in the morning, afternoon and evening from individuals in three study arms: treatment with the weight loss drug sibutramine/fasted, placebo/fed and placebo/fasted.ResultsThe results indicated that diurnal rhythm was the most significant driver of gene expression variation in the human adipose tissue, with at least 25% of the genes having had significant changes in their expression levels during the course of the day. The mRNA expression levels of core clock genes at a specific time of day were consistent across multiple subjects on different days in all three arms, indicating robust diurnal regulation irrespective of potential confounding factors. The genes essential for energy metabolism and tissue physiology were part of the diurnal signature. We hypothesize that the diurnal transition of the expression of energy metabolism genes reflects the shift in the adipose tissue from an energy-expending state in the morning to an energy-storing state in the evening. Consistent with this hypothesis, the diurnal transition was delayed by fasting and treatment with sibutramine. Finally, an in silico comparison of the diurnal signature with data from the publicly-available Connectivity Map demonstrated a significant association with transcripts that were repressed by mTOR inhibitors, suggesting a possible link between mTOR signaling, diurnal gene expression and metabolic regulation.ConclusionDiurnal rhythm plays an important role in the physiology and regulation of energy metabolism in the adipose tissue and should be considered in the selection of novel targets for the treatment of obesity and other metabolic disorders.


Blood | 2003

Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia

Bernard Fine; Martin Stanulla; Martin Schrappe; Minh Ho; Susanne Viehmann; Jochen Harbott; Linda M. Boxer


Cancer Research | 2005

A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.

Bernard Fine; Gertjan J. L. Kaspers; Minh Ho; Anne H. Loonen; Linda M. Boxer


Blood | 2005

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

Guillermo Garcia-Manero; Hui Yang; Blanca Sanchez-Gonzalez; Srdan Verstovsek; Alessandra Ferrajoli; Michael J. Keating; Michael Andreeff; Susan O’Brien; Jorge Cortes; William G. Wierda; Stefan Faderl; Charles Koller; Jan Davis; Gail Morris; Jean-Pierre Issa; Stanley R. Frankel; Victoria Richon; Bernard Fine; Hagop M. Kantarjian


Archive | 2006

Methods of using SAHA and Bortezomib for treating cancer

Stanley R. Frankel; Paul J. Deutsch; Sophia Randolph; Bernard Fine


Archive | 2013

translocations in acute lymphoblastic leukemia Gene expression patterns associated with recurrent chromosomal

Linda M. Boxer; Bernard Fine; Martin Stanulla; Martin Schrappe; Minh Ho; Susanne Viehmann; Jochen Harbott


Archive | 2008

Methods of treating cancers with saha, carboplatin

Bernard Fine; Paul J. Deutsch; Stanley R. Frankel; Sophia Randolph


Archive | 2006

Verfahren zur verwendung von saha und bortezomib für die behandlung von krebs

Stanley R. Frankel; Paul J. Deutsch; Sophia Randolph; Bernard Fine

Collaboration


Dive into the Bernard Fine's collaboration.

Top Co-Authors

Avatar

Stanley R. Frankel

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Sophia Randolph

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martin Stanulla

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge